E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies.
James A. de Lemos,David A. Morrow,David A. Morrow,C. Michael Gibson,C. Michael Gibson,Sabina A. Murphy,Sabina A. Murphy,Marc S. Sabatine,Marc S. Sabatine,Nader Rifai,Carolyn H. McCabe,Carolyn H. McCabe,Elliott M. Antman,Elliott M. Antman,Christopher P. Cannon,Christopher P. Cannon,Eugene Braunwald,Eugene Braunwald +17 more
TL;DR: In this paper, the authors defined the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS) and established that myoglobin may be useful for the early diagnosis of myocardial infarction (MI).
Journal ArticleDOI
An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.
TL;DR: With the exception of special groups of patients, such as those with ST segment depression and those who present relatively late, the benefits of thrombolytic therapy on survival have now been so clearly established that placebocontrolled trials are no longer needed, nor would they be needed.
Journal ArticleDOI
Pulmonary vascular dilution curves recorded by external detection in the diagnosis of left-to-right shunts
Roland Folse,Eugene Braunwald +1 more
TL;DR: A technique for the estimation of pulmonary blood flow is described by determining the clearance rate of inspired radioactive carbon dioxide with radiation counters placed over the chest; this method appears to be a sensitive one for detecting circulatory shunts.
Journal ArticleDOI
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Douglas L. Mann,Michael M. Givertz,Justin M. Vader,Randall C. Starling,Palak Shah,Steven McNulty,Kevin J. Anstrom,Kenneth B. Margulies,Michael S. Kiernan,Claudius Mahr,Divya Gupta,Margaret M. Redfield,Anuradha Lala,Gregory D. Lewis,Adam D. DeVore,Patrice Desvigne-Nickens,Adrian F. Hernandez,Eugene Braunwald,Life Investigators +18 more
TL;DR: In this paper, the authors compared the use of valsartan and sacubitril/valsartan in patients with advanced heart failure and a reduced ejection fraction and recent New York Heart Association class IV symptoms.
Journal ArticleDOI
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.
Brian A. Bergmark,Deepak L. Bhatt,Darren K. McGuire,Avivit Cahn,Ofri Mosenzon,Ph. Gabriel Steg,KyungAh Im,Estella Kanevsky,Yared Gurmu,Itamar Raz,Eugene Braunwald,Benjamin M. Scirica,Investigators +12 more
TL;DR: In a cohort of 12,156 patients with T2DM and high CV risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but notLower rates of the composite endpoint of CV death, MI, or ischemic stroke.